Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

By
Noshin Noorjahan
-
0
980
Allogene Therapeutics, Inc. announced that the US FDA granted RMAT designation to ALLO-316 for the treatment of adult patients with CD70 positive advanced or metastatic renal cell carcinoma.
[Allogene Therapeutics, Inc. (GlobenewsWire)]
Press Release